ClinicalTrials.Veeva

Menu

Comparing the Baerveldt and Paul Glaucoma Drainage Devices and Their Effects on the Corneal Endothelium

O

Oogziekenhuis Rotterdam

Status

Enrolling

Conditions

Glaucoma

Treatments

Device: Surgery/implantation

Study type

Interventional

Funder types

Other

Identifiers

NCT05344651
OZR-2020-30
NL80518.078.22 (Other Identifier)
MEC-2022-0069 (Other Identifier)

Details and patient eligibility

About

Rationale: The Baerveldt glaucoma drainage device (GDD) successfully reduces intraocular pressure but also involves a risk of corneal endothelial deterioration. Supposedly, the tip of a GDD tube with a thinner diameter, such as the Paul implant, will remain at a larger distance from the cornea and, thereby, cause less damage.

Objective: To determine whether the Paul tube induces less damage to the corneal endothelium than the Baerveldt GDD.

Study design: Randomized clinical trial. Study population: Phakic patients scheduled for surgical GDD implantation. Intervention: Either a Baerveldt or a Paul GDD implant. Main study parameters/endpoints: Endothelial cell density and tube position at 24 months.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The Paul GDD may have a less harmful effect on corneal endothelium. Otherwise, both GDDs will probably have a similar risk/benefit profile. The risks of study-related assessments are negligible, burden is low, extra time is about 5 x 1.5 h (total 7.5 h) in two years.

Enrollment

160 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age > 18 years.
  • Informed consent.
  • Caucasian ethnicity (to facilitate comparison of results with those of earlier work). Ethnicity will be based on self-reported origin of subject and/or parents.
  • Primary open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma.

Exclusion criteria

  • History of intraocular surgery (e.g. vitrectomy, cataract surgery, cyclodestructive procedures etc).
  • History of ocular comorbidity (e.g. active uveitis, proliferative diabetic retinopathy).
  • Pseudophakia.
  • Functionally monocular patients.
  • Need for glaucoma surgery combined with other ocular procedures (i.e. cataract surgery, keratoplasty, or retinal surgery) or an anticipated need for additional ocular surgery.
  • Narrow anterior chamber angle.
  • Best corrected visual acuity less than 0.1.
  • Severe blepharitis.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

160 participants in 2 patient groups

Baerveldt glaucoma drainage device
Active Comparator group
Treatment:
Device: Surgery/implantation
Paul glaucoma drainage device
Experimental group
Treatment:
Device: Surgery/implantation

Trial contacts and locations

1

Loading...

Central trial contact

Rene J Wubbels; Susan Marinissen

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems